A Phase 3 interventional study of Povorcitinib and Placebo in Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation. Completed at 101 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one has the largest enrollment, is the only one that started in 2023, is one of 6 in phase 3, and was the 4th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Canada
Ages 12–17
Incyte Corporation · Sites in United States
Ages 12–75
Incyte Corporation · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 619 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 391 across the 12 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
2 of the studies in Hidradenitis Suppurativa by Incyte Corporation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT07049575Incyte CorporationStudy to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | 2026-12-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Povorcitinib Dose A for 54 weeks.
Drug: Povorcitinib
Participants will receive Povorcitinib Dose B for 54 weeks.
Drug: Povorcitinib
Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.
Drug: Placebo
Oral, Tablet
Also known as: INCB054707
Oral, Tablet
Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 12
HiSCR50 is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count.
Time frame: Baseline; Week 12
Percentage of Participants Who Achieved HiSCR75 at Week 12
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: Baseline; Week 12
Percentage of Participants With Flare by Week 12
Participants who experienced at least 1 flare over 12 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.
Time frame: Baseline; Week 12
Percentage of Participants With at Least a 3-point Decrease in Skin Pain Numerical Rating Scale (NRS) Score at Week 12 Among Participants With a Baseline Skin Pain NRS Score ≥3
Participants with a Skin Pain score of at least 3 at baseline and who experienced at least a 3-point decrease in Skin Pain score at Week 12, relative to baseline, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain).
Time frame: Baseline; Week 12
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 12 Among Participants With a Baseline Skin Pain NRS Score of at Least 3
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 12, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain). analyzed.
Time frame: Baseline; Week 12
Percentage of Participants With at Least a 4-point Increase From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 12
Participants with a baseline FACIT-F score ≤48 and who experienced at least a 4-point increase in FACIT-F score at Week 12, relative to baseline, were assessed. The FACIT-F scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days, with scores for each item ranging from 0 (worst fatigue) to 4 (no fatigue). The total score is a sum of the 13 item scores and ranges from 0 (worst fatigue) to 52 (no fatigue).
Time frame: Baseline; Week 12
Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life.
Time frame: Baseline; up to Week 54
Mean Change From Baseline in DLQI Score at Each Visit During the Extension Period
The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life.
Time frame: Baseline; up to Week 54
Mean Change From Baseline in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; up to Week 54
Mean Change From Baseline in Abscess Count at Each Visit During the Extension Period
Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; up to Week 54
Percentage Change From Baseline (PCFB) in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
Time frame: Baseline; up to Week 54
Percentage Change From Baseline in Abscess Count at Each Visit During the Extension Period
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
Time frame: Baseline; up to Week 54
Mean Change From Baseline in Inflammatory Nodule Count at Each Visit at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; up to Week 54
Mean Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period
Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; up to Week 54
Percentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
Time frame: Baseline; up to Week 54
Percentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
Time frame: Baseline; up to Week 54
Mean Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; up to Week 54
Mean Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period
Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; up to Week 54
Percentage Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
Time frame: Baseline; up to Week 54
Percentage Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
Time frame: Baseline; up to Week 54
Percentage of Participants Who Achieved HiSCR50 at Week 24 for Participants Who Took Only Povorcitinib
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: Baseline; Week 24
Percentage of Participants Who Achieved HiSCR50 at Week 24 During the Extension Period
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: Baseline; Week 24
Percentage of Participants Who Achieved HiSCR75 at Week 24 for Participants Who Took Only Povorcitinib
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: Baseline; Week 24
Percentage of Participants Who Achieved HiSCR75 at Week 24 During the Extension Period
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: Baseline; Week 24
Percentage of Participants With Flare by Week 24 for Participants Who Took Only Povorcitinib
Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.
Time frame: Baseline; up to Week 24
Percentage of Participants With Flare by Week 24 During the Extension Period
Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.
Time frame: Baseline; up to Week 24
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.
Time frame: Baseline; Week 24
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.
Time frame: Baseline; Week 24
Percentage of Participants Who Achieved HiSCR50 at Week 54 for Participants Who Took Only Povorcitinib
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: Baseline; Week 54
Percentage of Participants Who Achieved HiSCR50 at Week 54 During the Extension Period
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: Baseline; Week 54
Percentage of Participants Who Achieved HiSCR75 at Week 54 for Participants Who Took Only Povorcitinib
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: Baseline; Week 54
Percentage of Participants Who Achieved HiSCR75 at Week 54 During the Extension Period
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: Baseline; Week 54
Percentage of Participants With Flare by Week 54 for Participants Who Took Only Povorcitinib
Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.
Time frame: Baseline; up to Week 54
Percentage of Participants With Flare at Week 54 During the Extension Period
Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.
Time frame: Baseline; up to Week 54
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.
Time frame: Baseline; Week 54
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.
Time frame: Baseline; Week 54
Percentage of Participants Who Achieved Maintenance of HiSCR50 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib
Maintenance of response is defined as achieving HiSCR50 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: up to 42 weeks (from end of Week 12 to end of Week 54)
Percentage of Participants Who Achieved Maintenance of HiSCR75 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib
Maintenance of response is defined as achieving HiSCR75 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
Time frame: up to 42 weeks (from end of Week 12 to end of Week 54)
Placebo-controlled Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.
Time frame: up to Week 16
Placebo-controlled Period: Number of Participants With ≥Grade 3 TEAEs
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to Week 16
Extension Period: Number of Participants With TEAEs
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.
Time frame: up to 46 weeks (from end of Week 12 to end of Week 58)
Extension Period: Number of Participants With ≥Grade 3 TEAEs
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to 46 weeks (from end of Week 12 to end of Week 58)
Overall Study Period: Number of Participants Who Took Only Povorcitinib With TEAEs
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.
Time frame: up to Week 58
Overall Study Period: Number of Participants Who Took Only Povorcitinib With ≥Grade 3 TEAEs
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to Week 58
| Milestone | Placebo | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|---|---|
| Started | 203 | 0 | 0 | 208 | 208 |
| Completed | 183 | 0 | 0 | 185 | 187 |
| Not completed | 20 | 0 | 0 | 23 | 21 |
| Withdrew: Lost to follow-up | 7 | 0 | 0 | 6 | 5 |
| Withdrew: Withdrawal by subject | 5 | 0 | 0 | 7 | 7 |
| Withdrew: Adverse event | 3 | 0 | 0 | 6 | 3 |
| Withdrew: Physician decision | 1 | 0 | 0 | 3 | 2 |
| Withdrew: Protocol deviation | 3 | 0 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Worsening of disease | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Not treated | 0 | 0 | 0 | 0 | 1 |
| Milestone | Placebo | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|---|---|
| Started | 0 | 90 | 92 | 184 | 188 |
| Completed | 0 | 56 | 56 | 114 | 124 |
| Not completed | 0 | 34 | 36 | 70 | 64 |
| Withdrew: Withdrawal by subject | 0 | 22 | 13 | 24 | 22 |
| Withdrew: Adverse event | 0 | 3 | 13 | 9 | 12 |
| Withdrew: Lack of efficacy | 0 | 3 | 5 | 15 | 12 |
| Withdrew: Lost to follow-up | 0 | 3 | 2 | 12 | 7 |
| Withdrew: Protocol deviation | 0 | 2 | 1 | 6 | 7 |
| Withdrew: Physician decision | 0 | 1 | 1 | 3 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Extended travel | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Captured as "early termination" in database | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Investigational product interrupted for longer than 28 days | 0 | 0 | 0 | 0 | 1 |
HiSCR50 is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 12 | 28.6 (22.5 to 35.3) | 42.3 (35.5 to 49.3) | 42.3 (35.5 to 49.3) |
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants Who Achieved HiSCR75 at Week 12 | 13.3 (9.0 to 18.8) | 25.5 (19.7 to 32.0) | 28.4 (22.3 to 35.0) |
Participants who experienced at least 1 flare over 12 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants With Flare by Week 12 | 33.5 (27.0 to 40.4) | 21.6 (16.2 to 27.9) | 20.7 (15.4 to 26.8) |
Participants with a Skin Pain score of at least 3 at baseline and who experienced at least a 3-point decrease in Skin Pain score at Week 12, relative to baseline, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain).
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants With at Least a 3-point Decrease in Skin Pain Numerical Rating Scale (NRS) Score at Week 12 Among Participants With a Baseline Skin Pain NRS Score ≥3 | 9.3 (5.2 to 15.1) | 29.1 (22.3 to 36.7) | 22.0 (15.8 to 29.3) |
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 12, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain). analyzed.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants Who Achieved Skin Pain NRS30 at Week 12 Among Participants With a Baseline Skin Pain NRS Score of at Least 3 | 17.9 (12.1 to 24.9) | 40.6 (33.0 to 48.5) | 37.7 (30.2 to 45.8) |
Participants with a baseline FACIT-F score ≤48 and who experienced at least a 4-point increase in FACIT-F score at Week 12, relative to baseline, were assessed. The FACIT-F scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days, with scores for each item ranging from 0 (worst fatigue) to 4 (no fatigue). The total score is a sum of the 13 item scores and ranges from 0 (worst fatigue) to 52 (no fatigue).
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants With at Least a 4-point Increase From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 12 | 32.1 | 45.1 | 46.1 |
The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life.
| scores on a scale | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Baseline | 12.52 ± 7.074 | 13.88 ± 7.500 | 12.86 ± 6.912 |
| Change from Baseline at Week 3 | -1.40 ± 4.435 | -3.88 ± 5.253 | -3.67 ± 5.425 |
| Change from Baseline at Week 6 | -1.12 ± 5.703 | -3.84 ± 6.526 | -4.09 ± 5.814 |
| Change from Baseline at Week 9 | -1.89 ± 5.712 | -3.39 ± 6.431 | -3.70 ± 5.832 |
| Change from Baseline at Week 12 | -1.22 ± 5.981 | -3.80 ± 6.976 | -4.04 ± 6.053 |
| Change from Baseline at Week 15 | — | -4.45 ± 6.500 | -3.97 ± 6.374 |
| Change from Baseline at Week 18 | — | -4.10 ± 6.974 | -4.08 ± 6.333 |
| Change from Baseline at Week 24 | — | -4.51 ± 7.163 | -4.66 ± 6.634 |
| Change from Baseline at Week 30 | — | -5.52 ± 7.377 | -4.03 ± 6.540 |
| Change from Baseline at Week 36 | — | -5.25 ± 7.086 | -4.11 ± 6.721 |
| Change from Baseline at Week 42 | — | -5.37 ± 6.943 | -4.31 ± 6.015 |
| Change from Baseline at Week 48 | — | -5.41 ± 7.129 | -5.53 ± 5.910 |
| Change from Baseline at Week 54 | — | -5.77 ± 7.026 | -5.08 ± 6.478 |
The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life.
| scores on a scale | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Baseline | 12.29 ± 6.798 | 12.24 ± 6.990 |
| Change from Baseline at Week 15 | -4.67 ± 4.698 | -4.53 ± 5.594 |
| Change from Baseline at Week 18 | -4.23 ± 5.789 | -4.47 ± 6.584 |
| Change from Baseline at Week 24 | -4.38 ± 5.802 | -4.14 ± 6.594 |
| Change from Baseline at Week 30 | -4.61 ± 5.552 | -4.76 ± 6.874 |
| Change from Baseline at Week 36 | -5.27 ± 6.428 | -4.98 ± 6.131 |
| Change from Baseline at Week 42 | -4.26 ± 7.287 | -5.78 ± 6.861 |
| Change from Baseline at Week 48 | -3.41 ± 7.446 | -5.16 ± 7.093 |
| Change from Baseline at Week 54 | -3.81 ± 7.307 | -5.26 ± 7.392 |
Change from baseline was calculated as the post-baseline value minus the baseline value.
| abscesses | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Baseline | 2.53 ± 3.813 | 2.07 ± 2.937 | 1.86 ± 3.451 |
| Change from Baseline at Week 3 | -0.25 ± 1.814 | -0.67 ± 1.983 | -0.34 ± 2.282 |
| Change from Baseline at Week 6 | -0.46 ± 2.214 | -0.88 ± 2.279 | -0.54 ± 2.385 |
| Change from Baseline at Week 9 | -0.59 ± 2.349 | -0.80 ± 2.424 | -0.50 ± 2.778 |
| Change from Baseline at Week 12 | -0.70 ± 2.776 | -0.91 ± 2.788 | -0.64 ± 2.807 |
| Change from Baseline at Week 15 | — | -1.19 ± 2.733 | -0.77 ± 2.883 |
| Change from Baseline at Week 18 | — | -1.28 ± 2.751 | -0.84 ± 2.941 |
| Change from Baseline at Week 24 | — | -1.20 ± 2.820 | -0.86 ± 2.708 |
| Change from Baseline at Week 30 | — | -0.95 ± 3.167 | -0.97 ± 2.746 |
| Change from Baseline at Week 36 | — | -1.22 ± 3.031 | -0.90 ± 2.638 |
| Change from Baseline at Week 42 | — | -1.23 ± 3.267 | -0.66 ± 2.753 |
| hange from Baseline at Week 48 | — | -1.15 ± 3.508 | -0.91 ± 2.706 |
| Change from Baseline at Week 54 | — | -1.14 ± 3.318 | -0.85 ± 2.816 |
Change from baseline was calculated as the post-baseline value minus the baseline value.
| abscesses | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Baseline | 2.27 ± 3.060 | 2.33 ± 3.835 |
| Change from Baseline at Week 15 | -1.13 ± 2.487 | -1.19 ± 2.828 |
| Change from Baseline at Week 18 | -1.13 ± 2.596 | -1.32 ± 3.218 |
| Change from Baseline at Week 24 | -1.35 ± 2.575 | -1.29 ± 3.227 |
| Change from Baseline at Week 30 | -1.20 ± 2.559 | -1.63 ± 3.376 |
| Change from Baseline at Week 36 | -1.26 ± 2.737 | -1.45 ± 3.255 |
| Change from Baseline at Week 42 | -1.18 ± 2.571 | -1.43 ± 3.827 |
| Change from Baseline at Week 48 | -1.14 ± 2.719 | -1.18 ± 3.500 |
| Change from Baseline at Week 54 | -1.41 ± 2.977 | -1.29 ± 3.530 |
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
| percentage change | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| PCFB at Week 3 | -16.48 ± 69.765 | -36.07 ± 60.391 | -19.38 ± 76.971 |
| PCFB at Week 6 | -15.80 ± 79.791 | -46.22 ± 67.273 | -26.70 ± 70.464 |
| PCFB at Week 9 | -20.57 ± 86.036 | -37.40 ± 89.384 | -34.40 ± 86.887 |
| PCFB at Week 12 | -23.53 ± 100.116 | -42.65 ± 100.243 | -39.41 ± 82.637 |
| PCFB at Week 15 | — | -61.44 ± 60.692 | -39.29 ± 85.053 |
| PCFB at Week 18 | — | -58.15 ± 70.831 | -49.89 ± 80.331 |
| PCFB at Week 24 | — | -49.13 ± 65.103 | -36.46 ± 101.579 |
| PCFB at Week 30 | — | -34.15 ± 137.637 | -48.94 ± 86.763 |
| PCFB at Week 36 | — | -52.20 ± 97.432 | -54.58 ± 75.387 |
| PCFB at Week 42 | — | -68.18 ± 52.199 | -48.74 ± 74.659 |
| PCFB at Week 48 | — | -53.60 ± 74.782 | -58.87 ± 72.812 |
| PCFB at Week 54 | — | -62.89 ± 57.292 | -54.52 ± 79.562 |
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
| percentage change | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| PCFB at Week 15 | -44.19 ± 96.423 | -45.15 ± 69.705 |
| PCFB at Week 18 | -49.55 ± 63.816 | -45.87 ± 67.735 |
| PCFB at Week 24 | -65.08 ± 49.248 | -43.81 ± 77.341 |
| PCFB at Week 30 | -56.37 ± 95.535 | -59.79 ± 54.822 |
| PCFB at Week 36 | -63.89 ± 70.178 | -57.50 ± 65.339 |
| PCFB at Week 42 | -57.96 ± 75.045 | -54.29 ± 86.756 |
| PCFB at Week 48 | -44.14 ± 109.130 | -43.42 ± 116.706 |
| PCFB at Week 54 | -69.52 ± 64.592 | -41.98 ± 90.298 |
Change from baseline was calculated as the post-baseline value minus the baseline value.
| inflammatory nodules | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Baseline | 8.55 ± 5.307 | 9.49 ± 7.803 | 10.19 ± 7.685 |
| Change from Baseline at Week 3 | -1.57 ± 3.877 | -2.68 ± 4.286 | -3.05 ± 4.307 |
| Change from Baseline at Week 6 | -1.97 ± 4.486 | -3.66 ± 4.305 | -4.16 ± 5.392 |
| Change from Baseline at Week 9 | -2.35 ± 4.814 | -4.35 ± 5.148 | -4.75 ± 6.237 |
| Change from Baseline at Week 12 | -2.04 ± 5.534 | -4.58 ± 5.330 | -4.60 ± 5.006 |
| Change from Baseline at Week 15 | — | -5.38 ± 6.644 | -5.47 ± 5.926 |
| Change from Baseline at Week 18 | — | -5.35 ± 6.539 | -5.87 ± 6.378 |
| Change from Baseline at Week 24 | — | -5.50 ± 7.220 | -6.43 ± 6.925 |
| Change from Baseline at Week 30 | — | -5.59 ± 6.618 | -6.59 ± 7.791 |
| Change from Baseline at Week 36 | — | -5.29 ± 6.431 | -6.42 ± 7.259 |
| Change from Baseline at Week 42 | — | -5.61 ± 6.229 | -6.33 ± 7.864 |
| Change from Baseline at Week 48 | — | -5.42 ± 6.291 | -6.65 ± 7.257 |
| Change from Baseline at Week 54 | — | -5.48 ± 6.182 | -6.40 ± 7.429 |
Change from baseline was calculated as the post-baseline value minus the baseline value.
| inflammatory nodules | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Baseline | 8.93 ± 5.641 | 8.51 ± 5.119 |
| Change from Baseline at Week 15 | -3.87 ± 4.747 | -3.95 ± 4.339 |
| Change from Baseline at Week 18 | -4.36 ± 4.511 | -4.91 ± 4.336 |
| Change from Baseline at Week 24 | -5.21 ± 4.698 | -4.85 ± 4.450 |
| Change from Baseline at Week 30 | -5.43 ± 4.284 | -5.29 ± 5.214 |
| Change from Baseline at Week 36 | -5.77 ± 5.634 | -5.31 ± 4.390 |
| Change from Baseline at Week 42 | -5.26 ± 5.444 | -5.91 ± 5.783 |
| Change from Baseline at Week 48 | -4.76 ± 6.954 | -5.51 ± 5.497 |
| Change from Baseline at Week 54 | -5.05 ± 6.645 | -5.30 ± 4.072 |
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
| percentage change | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| PCFB at Week 3 | -19.15 ± 40.712 | -26.67 ± 45.067 | -30.34 ± 38.085 |
| PCFB at Week 6 | -23.10 ± 55.564 | -37.49 ± 51.594 | -39.81 ± 46.070 |
| PCFB at Week 9 | -25.92 ± 58.998 | -44.12 ± 48.143 | -47.56 ± 49.033 |
| PCFB at Week 12 | -23.80 ± 62.444 | -47.61 ± 51.545 | -48.93 ± 47.827 |
| PCFB at Week 15 | — | -52.69 ± 45.812 | -54.51 ± 45.876 |
| PCFB at Week 18 | — | -53.12 ± 55.075 | -58.15 ± 43.417 |
| PCFB at Week 24 | — | -54.97 ± 61.697 | -62.27 ± 41.625 |
| PCFB at Week 30 | — | -56.22 ± 70.254 | -63.00 ± 45.082 |
| PCFB at Week 36 | — | -50.71 ± 98.451 | -63.66 ± 42.444 |
| PCFB at Week 42 | — | -58.02 ± 85.998 | -60.18 ± 53.924 |
| PCFB at Week 48 | — | -59.23 ± 90.813 | -64.79 ± 46.342 |
| PCFB at Week 54 | — | -56.95 ± 117.466 | -63.20 ± 45.420 |
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
| percentage change | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| PCFB at Week 15 | -46.63 ± 53.532 | -46.51 ± 40.505 |
| PCFB at Week 18 | -53.38 ± 50.552 | -59.03 ± 36.653 |
| PCFB at Week 24 | -61.09 ± 41.037 | -56.66 ± 39.079 |
| PCFB at Week 30 | -62.63 ± 45.226 | -61.73 ± 40.353 |
| PCFB at Week 36 | -52.89 ± 123.853 | -64.27 ± 35.847 |
| PCFB at Week 42 | -59.56 ± 54.000 | -70.21 ± 38.458 |
| Change from Baseline at Week 48 | -41.81 ± 159.447 | -67.60 ± 46.289 |
| PCFB at Week 54 | -60.30 ± 50.373 | -63.13 ± 40.078 |
Change from baseline was calculated as the post-baseline value minus the baseline value.
| draining tunnels | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Baseline | 2.95 ± 3.347 | 2.73 ± 3.172 | 2.52 ± 2.976 |
| Change from Baseline at Week 3 | 0.05 ± 1.753 | -0.54 ± 1.806 | -0.76 ± 2.225 |
| Change from Baseline at Week 6 | -0.29 ± 2.082 | -0.87 ± 2.162 | -1.01 ± 2.351 |
| Change from Baseline at Week 9 | -0.55 ± 2.208 | -0.88 ± 2.114 | -1.11 ± 2.282 |
| Change from Baseline at Week 12 | -0.37 ± 2.366 | -1.09 ± 2.152 | -1.06 ± 2.089 |
| Change from Baseline at Week 15 | — | -1.19 ± 2.286 | -1.08 ± 2.295 |
| Change from Baseline at Week 18 | — | -1.21 ± 2.329 | -1.06 ± 2.208 |
| Change from Baseline at Week 24 | — | -1.21 ± 2.585 | -1.23 ± 2.325 |
| Change from Baseline at Week 30 | — | -1.18 ± 3.154 | -1.27 ± 2.149 |
| Change from Baseline at Week 36 | — | -1.31 ± 2.938 | -1.39 ± 2.140 |
| Change from Baseline at Week 42 | — | -1.43 ± 2.869 | -1.30 ± 2.382 |
| Change from Baseline at Week 48 | — | -1.55 ± 2.872 | -1.44 ± 2.336 |
| Change from Baseline at Week 54 | — | -1.67 ± 2.729 | -1.35 ± 2.416 |
Change from baseline was calculated as the post-baseline value minus the baseline value.
| draining tunnels | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Baseline | 2.81 ± 3.538 | 3.12 ± 3.251 |
| Change from Baseline at Week 15 | -0.87 ± 2.552 | -1.18 ± 2.411 |
| Change from Baseline at Week 18 | -0.98 ± 2.845 | -1.20 ± 2.366 |
| Change from Baseline at Week 24 | -1.19 ± 2.775 | -1.05 ± 2.597 |
| Change from Baseline at Week 30 | -1.34 ± 2.837 | -1.25 ± 2.717 |
| Change from Baseline at Week 36 | -1.38 ± 2.352 | -1.04 ± 3.838 |
| Change from Baseline at Week 42 | -1.52 ± 2.374 | -1.09 ± 3.180 |
| Change from Baseline at Week 48 | -1.31 ± 2.866 | -1.38 ± 2.684 |
| Change from Baseline at Week 54 | -1.18 ± 2.842 | -1.43 ± 2.579 |
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
| percentage change | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| PCFB at Week 3 | -1.37 ± 81.971 | -20.47 ± 55.834 | -27.03 ± 58.237 |
| PCFB at Week 6 | -10.36 ± 101.112 | -36.80 ± 61.261 | -34.97 ± 70.126 |
| PCFB at Week 9 | -23.10 ± 84.928 | -32.84 ± 63.624 | -43.36 ± 72.695 |
| PCFB at Week 12 | -15.02 ± 91.581 | -42.88 ± 58.389 | -42.69 ± 64.219 |
| PCFB at Week 15 | — | -50.00 ± 58.914 | -42.25 ± 85.319 |
| PCFB at Week 18 | — | -47.44 ± 63.163 | -45.18 ± 72.834 |
| PCFB at Week 24 | — | -42.61 ± 75.780 | -52.04 ± 71.771 |
| PCFB at Week 30 | — | -31.11 ± 107.437 | -52.70 ± 81.691 |
| PCFB at Week 36 | — | -37.65 ± 106.728 | -58.46 ± 70.802 |
| PCFB at Week 42 | — | -44.69 ± 98.005 | -46.23 ± 118.337 |
| PCFB at Week 48 | — | -53.57 ± 63.118 | -56.05 ± 109.685 |
| PCFB at Week 54 | — | -57.71 ± 61.752 | -51.91 ± 130.770 |
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.
| percentage change | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| PCFB at Week 15 | -30.60 ± 102.030 | -43.81 ± 57.304 |
| PCFB at Week 18 | -30.58 ± 149.719 | -46.06 ± 56.989 |
| PCFB at Week 24 | -41.06 ± 107.121 | -34.02 ± 87.701 |
| PCFB at Week 30 | -61.76 ± 62.225 | -56.13 ± 58.982 |
| PCFB at Week 36 | -67.31 ± 50.116 | -52.72 ± 68.217 |
| PCFB at Week 42 | -60.18 ± 75.984 | -39.03 ± 100.063 |
| PCFB at Week 48 | -51.57 ± 69.588 | -49.85 ± 110.572 |
| PCFB at Week 54 | -45.78 ± 80.657 | -48.12 ± 100.908 |
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants Who Achieved HiSCR50 at Week 24 for Participants Who Took Only Povorcitinib | — | 57.1 (49.1 to 64.9) | 57.9 (49.8 to 65.6) |
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Percentage of Participants Who Achieved HiSCR50 at Week 24 During the Extension Period | 58.0 (46.5 to 68.9) | 56.3 (45.3 to 66.9) |
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants Who Achieved HiSCR75 at Week 24 for Participants Who Took Only Povorcitinib | — | 37.3 (29.8 to 45.2) | 40.3 (32.6 to 48.3) |
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Percentage of Participants Who Achieved HiSCR75 at Week 24 During the Extension Period | 38.3 (27.7 to 49.7) | 31.0 (21.5 to 41.9) |
Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants With Flare by Week 24 for Participants Who Took Only Povorcitinib | — | 17.8 (12.8 to 23.8) | 19.6 (14.4 to 25.7) |
Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.
| percentage of participants | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Percentage of Participants With Flare by Week 24 During the Extension Period | 6.7 (2.5 to 14.1) | 5.4 (1.8 to 12.2) |
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib | — | 55.0 (45.7 to 64.1) | 61.5 (51.0 to 71.2) |
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.
| percentage of participants | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3 | 65.5 (51.4 to 77.8) | 52.5 (39.1 to 65.7) |
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants Who Achieved HiSCR50 at Week 54 for Participants Who Took Only Povorcitinib | — | 67.5 (58.1 to 76.0) | 57.3 (48.1 to 66.1) |
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Percentage of Participants Who Achieved HiSCR50 at Week 54 During the Extension Period | 64.3 (50.4 to 76.6) | 71.4 (57.8 to 82.7) |
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants Who Achieved HiSCR75 at Week 54 for Participants Who Took Only Povorcitinib | — | 57.0 (47.4 to 66.3) | 46.8 (37.8 to 55.9) |
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Percentage of Participants Who Achieved HiSCR75 at Week 54 During the Extension Period | 48.2 (34.7 to 62.0) | 44.6 (31.3 to 58.5) |
Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants With Flare by Week 54 for Participants Who Took Only Povorcitinib | — | 22.3 (16.7 to 28.6) | 23.0 (17.4 to 29.4) |
Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.
| percentage of participants | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Percentage of Participants With Flare at Week 54 During the Extension Period | 15.7 (8.9 to 25.0) | 9.8 (4.6 to 17.8) |
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.
| percentage of participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib | — | 59.5 (47.9 to 70.4) | 64.5 (52.7 to 75.1) |
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.
| percentage of participants | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3 | 66.7 (49.0 to 81.4) | 54.1 (36.9 to 70.5) |
Maintenance of response is defined as achieving HiSCR50 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|
| Week 15 | 84.3 (74.7 to 91.4) | 79.1 (69.0 to 87.1) |
| Week 18 | 84.0 (74.1 to 91.2) | 79.8 (69.6 to 87.7) |
| Week 24 | 76.9 (66.0 to 85.7) | 77.5 (66.8 to 86.1) |
| Week 30 | 74.0 (62.4 to 83.5) | 74.7 (63.3 to 84.0) |
| Week 36 | 85.1 (74.3 to 92.6) | 73.2 (61.4 to 83.1) |
| Week 42 | 78.1 (66.0 to 87.5) | 68.2 (55.6 to 79.1) |
| Week 48 | 80.3 (68.2 to 89.4) | 71.6 (59.3 to 82.0) |
| Week 54 | 73.8 (60.9 to 84.2) | 70.8 (58.2 to 81.4) |
Maintenance of response is defined as achieving HiSCR75 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.
| percentage of participants | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|
| Week 15 | 78.0 (64.0 to 88.5) | 80.7 (68.1 to 90.0) |
| Week 18 | 85.1 (71.7 to 93.8) | 74.5 (61.0 to 85.3) |
| Week 24 | 76.6 (62.0 to 87.7) | 69.8 (55.7 to 81.7) |
| Week 30 | 73.3 (58.1 to 85.4) | 62.0 (47.2 to 75.3) |
| Week 36 | 76.2 (60.5 to 87.9) | 66.0 (50.7 to 79.1) |
| Week 42 | 82.5 (67.2 to 92.7) | 59.1 (43.2 to 73.7) |
| Week 48 | 71.1 (54.1 to 84.6) | 60.0 (44.3 to 74.3) |
| Week 54 | 68.4 (51.3 to 82.5) | 65.9 (50.1 to 79.5) |
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.
| Participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Placebo-controlled Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 99 | 130 | 131 |
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|---|
| Placebo-controlled Period: Number of Participants With ≥Grade 3 TEAEs | 5 | 8 | 6 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.
| Participants | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Extension Period: Number of Participants With TEAEs | 63 | 71 |
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Placebo to Povorcitinib 45 mg QD | Placebo to Povorcitinib 75 mg QD |
|---|---|---|
| Extension Period: Number of Participants With ≥Grade 3 TEAEs | 5 | 7 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.
| Participants | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|
| Overall Study Period: Number of Participants Who Took Only Povorcitinib With TEAEs | 164 | 171 |
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD |
|---|---|---|
| Overall Study Period: Number of Participants Who Took Only Povorcitinib With ≥Grade 3 TEAEs | 18 | 17 |
Collected over Adverse events (AEs) were reported from the first dose of study treatment up to approximately 58 weeks for povorcitinib and for up to 16 weeks for placebo.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PC Period: Povorcitinib 45 mg QD | 0/208 (0%) | 4/208 (1.9%) | 61/208 (29.3%) |
| PC Period: Povorcitinib 75 mg QD | 0/207 (0%) | 4/207 (1.9%) | 75/207 (36.2%) |
| PC Period: Placebo | 0/203 (0%) | 5/203 (2.5%) | 38/203 (18.7%) |
| Any Povorcitinib 45 mg | 0/298 (0%) | 19/298 (6.4%) | 142/298 (47.7%) |
| Any Povorcitinib 75 mg | 0/299 (0%) | 19/299 (6.4%) | 150/299 (50.2%) |
| Event | PC Period: Povorcitinib 45 mg QD | PC Period: Povorcitinib 75 mg QD | PC Period: Placebo | Any Povorcitinib 45 mg | Any Povorcitinib 75 mg |
|---|---|---|---|---|---|
| HidradenitisSkin and subcutaneous tissue disorders | 2/208 | 2/207 | 0/203 | 7/298 | 5/299 |
| CellulitisInfections and infestations | 0/208 | 0/207 | 0/203 | 1/298 | 2/299 |
| AppendicitisInfections and infestations | 0/208 | 0/207 | 1/203 | 0/298 | 0/299 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/208 | 0/207 | 1/203 | 0/298 | 0/299 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/208 | 0/207 | 1/203 | 0/298 | 0/299 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/208 | 0/207 | 1/203 | 0/298 | 0/299 |
| Scrotal cellulitisInfections and infestations | 0/208 | 0/207 | 1/203 | 0/298 | 0/299 |
| DepressionPsychiatric disorders | 0/208 | 1/207 | 0/203 | 0/298 | 1/299 |
| Faeces discolouredGastrointestinal disorders | 0/208 | 1/207 | 0/203 | 0/298 | 1/299 |
| Pyoderma gangrenosumSkin and subcutaneous tissue disorders | 0/208 | 1/207 | 0/203 | 0/298 | 1/299 |
| Event | PC Period: Povorcitinib 45 mg QD | PC Period: Povorcitinib 75 mg QD | PC Period: Placebo | Any Povorcitinib 45 mg | Any Povorcitinib 75 mg |
|---|---|---|---|---|---|
| AcneSkin and subcutaneous tissue disorders | 18/208 | 24/207 | 11/203 | 49/298 | 63/299 |
| Upper respiratory tract infectionInfections and infestations | 12/208 | 12/207 | 6/203 | 27/298 | 33/299 |
| NasopharyngitisInfections and infestations | 10/208 | 16/207 | 9/203 | 28/298 | 32/299 |
| COVID-19Infections and infestations | 8/208 | 11/207 | 7/203 | 22/298 | 28/299 |
| HeadacheNervous system disorders | 14/208 | 16/207 | 7/203 | 22/298 | 26/299 |
| Blood creatine phosphokinase increasedInvestigations | 7/208 | 6/207 | 1/203 | 17/298 | 13/299 |
| HypertensionVascular disorders | 4/208 | 3/207 | 1/203 | 10/298 | 17/299 |
| InfluenzaInfections and infestations | 3/208 | 4/207 | 1/203 | 15/298 | 12/299 |
| DiarrhoeaGastrointestinal disorders | 3/208 | 4/207 | 1/203 | 10/298 | 15/299 |
| Age, Continuous(years) | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD | Total |
|---|---|---|---|---|
| Mean | 37.8 ± 11.71 | 37.4 ± 11.43 | 35.6 ± 10.97 | 36.9 ± 11.39 |
| Sex: Female, Male(Participants) | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD | Total |
|---|---|---|---|---|
| Female | 110 | 134 | 123 | 367 |
| Male | 93 | 74 | 85 | 252 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 21 | 32 | 31 | 84 |
| Not Hispanic or Latino | 174 | 168 | 163 | 505 |
| Unknown or Not Reported | 8 | 8 | 14 | 30 |
| Race/Ethnicity, Customized(Participants) | Placebo | Povorcitinib 45 mg QD | Povorcitinib 75 mg QD | Total |
|---|---|---|---|---|
| White | 162 | 156 | 159 | 477 |
| Black/African American | 21 | 30 | 25 | 76 |
| Asian | 7 | 3 | 0 | 10 |
| American Indian/Alaska Native | 1 | 1 | 1 | 3 |
| Not Reported | 5 | 8 | 13 | 26 |
| Unknown | 0 | 1 | 1 | 2 |
| Pakistani | 1 | 1 | 0 | 2 |
| Bengali | 1 | 0 | 0 | 1 |
| Captured as "Hispanic" in Database | 1 | 0 | 0 | 1 |
| Arab | 1 | 0 | 0 | 1 |
| Mixed Race | 1 | 0 | 0 | 1 |
| Black and White | 1 | 0 | 0 | 1 |
| Middle Eastern | 1 | 0 | 2 | 3 |
| Persian | 0 | 1 | 0 | 1 |
| Indian | 0 | 1 | 0 | 1 |
| Captured as "First Nations" in Database | 0 | 1 | 0 | 1 |
| South American | 0 | 1 | 0 | 1 |
| Puerto Rican | 0 | 1 | 1 | 2 |
| Mexican | 0 | 3 | 1 | 4 |
| Aboriginal | 0 | 0 | 2 | 2 |
| Captured as "Hispanic or Latino" in Database | 0 | 0 | 1 | 1 |
| Captured as "Latina" in Database | 0 | 0 | 1 | 1 |
| Half Asian, Half Black | 0 | 0 | 1 | 1 |
Showing the first 100 of 101 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Feb 2023 to primary completion in Jan 2025, 22 months.
Results were first posted in Nov 2026, 1 year 9 months after primary completion. A results delay was requested in Jan 2026.
Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Povorcitinib